These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 19957009)
21. Association between seasonal factors and multiple sclerosis. Watad A; Azrielant S; Soriano A; Bracco D; Abu Much A; Amital H Eur J Epidemiol; 2016 Nov; 31(11):1081-1089. PubMed ID: 27226079 [TBL] [Abstract][Full Text] [Related]
22. T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention. van Langelaar J; van der Vuurst de Vries RM; Janssen M; Wierenga-Wolf AF; Spilt IM; Siepman TA; Dankers W; Verjans GMGM; de Vries HE; Lubberts E; Hintzen RQ; van Luijn MM Brain; 2018 May; 141(5):1334-1349. PubMed ID: 29659729 [TBL] [Abstract][Full Text] [Related]
23. Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies. Maggi P; Absinta M; Grammatico M; Vuolo L; Emmi G; Carlucci G; Spagni G; Barilaro A; Repice AM; Emmi L; Prisco D; Martinelli V; Scotti R; Sadeghi N; Perrotta G; Sati P; Dachy B; Reich DS; Filippi M; Massacesi L Ann Neurol; 2018 Feb; 83(2):283-294. PubMed ID: 29328521 [TBL] [Abstract][Full Text] [Related]
24. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Thorpe JW; Kidd D; Moseley IF; Kenndall BE; Thompson AJ; MacManus DG; McDonald WI; Miller DH Neurology; 1996 Feb; 46(2):373-8. PubMed ID: 8614497 [TBL] [Abstract][Full Text] [Related]
25. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Bates D Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678 [TBL] [Abstract][Full Text] [Related]
26. A Case of Multiple Sclerosis-Like Relapsing Remitting Encephalomyelitis Following Allogeneic Hematopoietic Stem Cell Transplantation and a Review of the Published Literature. Das J; Gill A; Lo C; Chan-Lam N; Price S; Wharton SB; Jessop H; Sharrack B; Snowden JA Front Immunol; 2020; 11():668. PubMed ID: 32431694 [TBL] [Abstract][Full Text] [Related]
27. Hyperprolactinemia and immunohistochemical expression of intracellular prolactin and prolactin receptor in primary central nervous system tumors and their relationship with cellular replication. Soares Leães CG; Filho AP; Pereira Lima JF; Dallago CM; Batista RL; Barbosa-Coutinho LM; Ferreira NP; da Costa Oliveira M Brain Tumor Pathol; 2007; 24(2):41-6. PubMed ID: 18095129 [TBL] [Abstract][Full Text] [Related]
29. Alopecia in preexisting autoimmune thyroid disease in family medicine practice: can hyperprolactinemia induce hair loss? A case report. Bosnić Z; Šarić B; Vučić D; Kovačević B; Marinić N; Volarić M; Trtica Majnarić L Acta Dermatovenerol Alp Pannonica Adriat; 2021 Jun; 30(2):75-77. PubMed ID: 34169704 [TBL] [Abstract][Full Text] [Related]
30. Susceptibility-weighted imaging in the differential diagnosis of autoimmune central nervous system vasculitis and multiple sclerosis. Huang X; Lu T; Guo Z; Wei L; Chen S; Qiu W; Lu Z Mult Scler Relat Disord; 2019 Aug; 33():70-74. PubMed ID: 31158805 [TBL] [Abstract][Full Text] [Related]
31. Demographic and clinical profile of Multiple Sclerosis in Kashmir: A short report. Zahoor I; Asimi R; Haq E; Yousuf Wani I Mult Scler Relat Disord; 2017 Apr; 13():103-106. PubMed ID: 28427689 [TBL] [Abstract][Full Text] [Related]
32. Prolactin and autoimmunity: The hormone as an inflammatory cytokine. Borba VV; Zandman-Goddard G; Shoenfeld Y Best Pract Res Clin Endocrinol Metab; 2019 Dec; 33(6):101324. PubMed ID: 31564625 [TBL] [Abstract][Full Text] [Related]
33. Revised diagnostic criteria of multiple sclerosis. Milo R; Miller A Autoimmun Rev; 2014; 13(4-5):518-24. PubMed ID: 24424194 [TBL] [Abstract][Full Text] [Related]
34. Hyperprolactinemia in some Meniere patients even in the absence of incapacitating vertigo. Falkenius-Schmidt K; Rydmarker S; Horner KC Hear Res; 2005 May; 203(1-2):154-8. PubMed ID: 15855040 [TBL] [Abstract][Full Text] [Related]
35. Chaos theory for clinical manifestations in multiple sclerosis. Akaishi T; Takahashi T; Nakashima I Med Hypotheses; 2018 Jun; 115():87-93. PubMed ID: 29685206 [TBL] [Abstract][Full Text] [Related]
36. Paediatric multiple sclerosis: the experience of the German Centre for Multiple Sclerosis in Childhood and Adolescence. Stark W; Huppke P; Gärtner J J Neurol; 2008 Dec; 255 Suppl 6():119-22. PubMed ID: 19300972 [TBL] [Abstract][Full Text] [Related]
37. Fractal dimension analysis of grey matter in multiple sclerosis. Esteban FJ; Sepulcre J; de Miras JR; Navas J; de Mendizábal NV; Goñi J; Quesada JM; Bejarano B; Villoslada P J Neurol Sci; 2009 Jul; 282(1-2):67-71. PubMed ID: 19167728 [TBL] [Abstract][Full Text] [Related]
38. The increasing incidence and prevalence of female multiple sclerosis--a critical analysis of potential environmental factors. Sellner J; Kraus J; Awad A; Milo R; Hemmer B; Stüve O Autoimmun Rev; 2011 Jun; 10(8):495-502. PubMed ID: 21354338 [TBL] [Abstract][Full Text] [Related]
39. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. Wujek JR; Bjartmar C; Richer E; Ransohoff RM; Yu M; Tuohy VK; Trapp BD J Neuropathol Exp Neurol; 2002 Jan; 61(1):23-32. PubMed ID: 11829341 [TBL] [Abstract][Full Text] [Related]
40. Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects. Pender MP; Wolfe NP Intern Med J; 2002 Nov; 32(11):554-63. PubMed ID: 12412939 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]